Avalo Therapeutics, Inc. Common StockAVTX

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1 pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1 monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa.

avalotx.com